RT Journal Article
SR Electronic
T1 Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr0920080873
DO 10.1136/bcr.09.2008.0873
VO 2009
A1 Shu-Chen Kuo
A1 Hui-Ting Lee
A1 Wei-Sheng Chen
A1 Chung-Tei Chou
A1 Chang-Youh Tsai
YR 2009
UL http://casereports.bmj.com/content/2009/bcr.09.2008.0873.abstract
AB To report a hepatitis B virus (HBV) reactivation during the treatment of etanercept for rheumatoid arthritis (RA).The chronological course of a patient with RA who developed HBV reactivation associated with etanercept treatment was recorded.A Taiwanese woman with RA was treated by etanercept. A severe deterioration of liver biochemistry occurred soon after the start of the biologicals because of the previously unrecognised HBV carrier status. The condition was successfully alleviated by oral lamivudine administration.In the prevalent area of HBV, viral titre monitoring and pre-emptive antiviral treatment may be fundamentally important to avoid serious complications of HBV reactivation whenever a new treatment modality such as biologicals is started for patients with RA.